A Critical Evaluation of the Role of Soy Protein and Isoflavone Supplementation in the Control of Plasma Cholesterol Concentrations
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Context: The purpose of this review was to critically evaluate current research on the effect of soy protein and isoflavone supplements on plasma lipoproteins and place the potential role of soy in the prevention of coronary artery disease (CAD) into a clinical perspective. Evidence Acquisition: An extensive literature search was performed using a variety of medical and scientific databases including Medline, PubMed, Science Direct, Ovid, NIST, and Infotrac to identify relevant articles. Journal articles were cross-referenced for additional sources of information. Articles were evaluated based on level of experimental control as well as statistical, quantitative, and clinical analysis. Evidence Synthesis: Soy and soy isoflavones have been the object of extensive research investigating their potential hypocholesterolemic effects and possible role in the prevention of CAD. It has been suggested that soy, especially the isoflavones contained in soy, improves lipoprotein levels, thus reducing the risk for CAD. This belief, however, is not uniformly accepted. Moreover, the experimental evidence in support of this notion is not as overwhelming as generally perceived, and the current available data reveal that the discrepancies observed are primarily statistical in nature rather than reflecting actual quantitative differences in the hypocholesterolemic effects detected. Conclusions: A critical analysis of the investigations to date indicates the data are not quantitatively impressive and raises substantial questions about the clinical importance of the hypocholesterolemic effects observed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The detrimental effects of a high-carbohydrate diet on TGs occur mainly when refined carbohydrate-rich foods are consumed, while they are much less prominent if the diet is based largely on fibrerich, low-glycaemic index foods. This applies particularly to people with DM or MetS [171,172].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [172]
In the citing paper
“Soy protein has been indicated as being able to induce a modest LDL-C-lowering effect when replacing animal protein foods. 151”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [151]
In the citing paper
“However, this was not confirmed when changes in other dietary components were taken into account.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [151]
In the citing paper
“Soy protein has been indicated as being able to induce a modest LDL-C-lowering effect when replacing animal protein foods.151”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [151]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids
Anderson, J. W., Johnstone, B. M., & Cook-Newell, M. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330502 · Cited by 2,048
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720 · cited 3×
“Isolated soy isoflavones have been introduced in amounts from 28 to 150 mg and have achieved nonstatistical reductions in LDL-cholesterol in range of between 1 and 6.5% (Table 2). Statins, on the other hand, generally have been associated with reductions in LDL-cholesterol of between 30 and 60%, depending on dose and…”
BackgroundInfluentialKrauss, R. M., Eckel, R. H., Howard, B., Appel, L. J., Daniels, S. R., Deckelbaum, R. J., Erdman, J. W., Kris-Etherton, P., Goldberg, I. J., Kotchen, T. A., et al. (2000) · Circulation · doi:10.1161/01.cir.102.18.2284 · Cited by 1,458
Setchell, K. D. R., Brown, N. M., & Lydeking-Olsen, E. (2002) · The Journal of Nutrition · doi:10.1093/jn/132.12.3577 · Cited by 1,209
Dietary Isoflavones: Biological Effects and Relevance to Human Health
Setchell, K. D. R., & Cassidy, A. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.3.758s · Cited by 1,158
Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones
Kenneth, D. S. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1333s · Cited by 1,128
Isoflavone Content in Commercial Soybean Foods
Wang, H., & Murphy, P. A. (1994) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf00044a016 · Cited by 996
Research works printed but not linked: 5
- 1999, Food labeling: health claims; soy protein and coronary artery disease., Fed Regist, 64, 57699
- 2001, Soyfoods: The U.S. Market 2001
- Lydeking-Olsen, 2002, Lipoprotein effects of soy milk and progesterone for prevention of bone loss in post menopausal hypercholesterolemic women, J Nutr, 132, 608S
- Kotsonis, 2001, Food toxicology, In: Klaassen Curtis, ed. Casarett and Doull’s toxicology: the basic science of poisons 6th ed. New York: McGraw-Hill Medical Publishing Division;, 1049
- Frölich, Eur J Clin Nutr, 49, 116
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Metadata
- Authors
- Dewell, A., Hollenbeck, P. L. W., & Hollenbeck, C. B.
- Affiliations
- San Jose State University (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Hollenbeck, Clarie B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-03-01
- Volume
- 91
- Issue
- 3
- Pages
- 772-780
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2089404194
- Cited by
- 90
- References
- 91
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 3 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 7 · 2013: 8 · 2012: 5
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Phytoestrogen effects and research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Natural Products and Biological Research
- Keywords
- soy protein, soy isoflavones, cholesterol-lowering effect, serum cholesterol, serum lipoproteins, coronary heart disease prevention, dietary supplementation
- MeSH terms
- Cholesterol, Coronary Disease, Humans, Isoflavones, Dietary Supplements, Soybean Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Critical Evaluation of the Role of Soy Protein and Isoflavone Supplementation in the Control of Plasma Cholesterol Concentrations. https://app.cochat.ai/papers/10.1210/jc.2004-2350
- The paper
- Dewell, A., Hollenbeck, P. L. W., & Hollenbeck, C. B. (2006). A Critical Evaluation of the Role of Soy Protein and Isoflavone Supplementation in the Control of Plasma Cholesterol Concentrations. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2004-2350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.